In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 1 selected

Type

Guidance programme

Showing 1 to 4 of 4

TitleConsultationTypeConsultation end date
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]Draft guidanceTechnology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]Draft guidanceTechnology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer [ID6168]Final draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All